【摘要】 目的观察健脾解毒方联合化疗治疗II-III期大肠癌术后患者的临床疗效及其对免疫功能的影响。方法将40例大肠癌患者按随机数字表法分为治疗组、对照组各20例。两组患者化疗均采用FOLFOX4化疗方案,治疗组加服健脾解毒方汤剂(每日1剂,连服8周),化疗每2周重复1次,1次为1个周期,连用4个周期后观察两组临床疗效及其免疫功能的变化。结果治疗结束后治疗组中医证候改善的总有效率高于对照组,差异有统计学意义(P<0.05);两组患者的中医证候总积分均较治疗前有所改善,两组间比较差异有统计学意义(P<0.01);治疗后治疗组在KPS评分疗效及体质量增加方面优于对照组,差异有统计学意义(P<0.05);在免疫学指标CD3+、CD4+、CD4+/CD8+值改善方面优于对照组,差异具有显著统计学意义(P<0.01)。结论健脾解毒方能提高大肠癌化疗患者的临床疗效,改善生活质量,并增强机体免疫力。更多还原

【Abstract】 Objective To observe the clinical efficacy of Jianpi Jiedu Fang(JPJDF) combined with chemotherapy on the treatment of patients with stage II-III colorectal cancer after operation and its effects on immune function. Methods The 40 cases of colorectal cancer were divided into two groups, treatment group and control group, 20 cases in each group. Patients of two groups were treated with FOLFOX4 chemotherapy, but the treatment group was given JPJDF(one dose every day,continuously for 8 weeks). Every 2 weeks repeated 1 times, 1 times for 1 cycles, the clinical efficacy and immune function in the two groups were observed after 4 cycles. Results After the end of observation, the total efficiency of the treatment group was higher than that of the control group(P <0.05); the total scores of TCM syndromes in patients of the two groups were improved after treatment, there were differences between the two groups(P<0.01). After the end of treatment,the KPS score of treatment group was better than the control group, the difference was statistically significant(P<0.05); the CD3+, CD4+, CD4+/CD8+index value was better than the control group, the difference was significant(P<0.01). Conclusion JPJDF can increasethe clinical efficacy, improve the quality of life and enhance the immune function of patients with colorectal cancer.更多还原